Stock Taper 
KEY STATISTICS
COMPANY
LEADERSHIP
COMPENSATION 2026
ABOUT
PRICE TARGET
UPCOMING EARNINGS
SPLIT RECORD
| DATE | TYPE | RATIO |
|---|---|---|
| 2024-08-09 | Reverse | 1:12 |
| 2023-11-30 | Reverse | 1:20 |
ETFS HOLDING THIS STOCK
INSTITUTIONAL OWNERSHIP
PRICE
$4.87 ▼ DOWN 0.41% (−$0.02)About Cingulate Inc.
https://www.cingulate.com ↗Cingulate Inc. is a clinical-stage biopharmaceutical company developing treatments for ADHD and anxiety, with lead candidates CTx-1301 (phase 3) and CTx-1302, based in Kansas City, Kansas.
INDUSTRY
A PRODUCT CINGULATE INC. IS KNOWN FOR
CTx-1301 is a late-stage, once-daily ADHD treatment by Cingulate, utilizing their proprietary PTR™ platform, with an FDA-submitted NDA, offering fast onset and all-day efficacy.
Cingulate in 2025
Cingulate Inc. Announces FDA Acceptance of New Drug Application for ADHD Treatment CTx-1301, PDUFA Date Set for May 2026
In October 2025, the U.S. Food and Drug Administration (FDA) accepted Cingulate's New Drug Application (NDA) for CTx-1301, its lead candidate for the treatment of ADHD. This acceptance confirmed the submission was complete and permitted a substantive review, representing a critical milestone for the company and its path toward potential commercialization.
Cingulate Inc. Submits New Drug Application for Lead ADHD Asset CTx-1301, Pivoting Towards Commercialization
In a pivotal strategic shift, Cingulate Inc. submitted its New Drug Application (NDA) to the FDA for its lead ADHD treatment, CTx-1301, on July 31, 2025. This marked the company's transition from a clinical-stage to a pre-commercial biopharmaceutical company, with subsequent actions in 2025 focused on preparing for a potential 2026 market launch.
RATINGS SNAPSHOT
Overall rating: C
MOST RECENT ANALYST GRADES
SECTORS PEERS
| PEER | PRICE | |
|---|---|---|
 BCTX | $3.96 | COMPARE |
 ALLR | $0.98 | COMPARE |
 SYBX | $1.10 | COMPARE |
 NCNA | $1.08 | COMPARE |
 LEXX | $3.25 | COMPARE |